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http://dx.doi.org/10.1016/j.jacl.2012.07BACKGROUND: Icosapent ethyl (IPE; formerly AMR101) is a high-purity prescription form of
eicosapentaenoic acid ethyl ester. In the MARINE study we evaluated the efficacy and safety of IPE
in patients with very high triglycerides (TG; $500 mg/dL) and previously demonstrated significant re-
ductions in TG levels with no significant increases in low-density lipoprotein (LDL) cholesterol levels.
OBJECTIVES: In this follow-up, exploratory analysis, we report the effects of IPE on lipoprotein
particle concentration and size.
METHODS: MARINE was a phase 3, multicenter, placebo-controlled, randomized, double-blind,
12-week study. Hypertriglyceridemic patients (N 5 229) were randomized to three treatment groups:
IPE 4 g/day, IPE 2 g/day, or placebo. Lipoprotein particle concentrations and sizes were measured by
nuclear magnetic resonance spectroscopy.
RESULTS: Compared with placebo, IPE 4 g/day significantly reduced median concentrations of
large very-low-density lipoprotein (VLDL; 227.9%; P 5 .0211), total LDL (216.3%; P 5 .0006),
small LDL (225.6%; P , .0001), and total high-density lipoprotein (HDL; 27.4%; P 5 .0063) par-
ticles and reduced VLDL particle size (28.6%; P 5 .0017). In this patient population with TG
$500 mg/dL, IPE did not significantly change the overall sizes of LDL or HDL particles.
CONCLUSION: IPE 4 g/day significantly reduced large VLDL, total LDL, small LDL, and total
HDL particle concentrations and VLDL particle size in patients with TG $500 mg/dL. Changes in
VLDL particle concentration and size reflect the TG-lowering effects of eicosapentaenoic acid. The
reduction in LDL particle concentration with IPE is novel among u-3 therapies and is consistent
with the previously reported reduction in apolipoprotein B and lack of LDL-C increase with IPE in
patients with very high TG levels. Clinical trial registration number: NCT01047683.
 2012 National Lipid Association. All rights reserved.ted for publication July 15, 2012.
National Lipid Association. All rights reserved.
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Hypertriglyceridemia is directly associated with an
increased risk of atherosclerotic coronary heart disease
(CHD).1 Consumption of the marine u-3 fatty acids eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA)
lowers triglyceride (TG) plasma levels.2 However,
TG-lowering therapies containing both EPA and DHA
may increase low-density lipoprotein (LDL) cholesterol,
especially in patients with marked elevations of TGs at
baseline.3 In previous smaller studies of patients with nor-
mal to moderately elevated TG levels, purified EPA re-
duced TG levels without increasing LDL cholesterol
levels.4–9
Icosapent ethyl (IPE; Vascepa [formerly AMR101];
Amarin, Bedminster, NJ) is a high-purity prescription
form of EPA ethyl ester approved by the United States
Food and Drug Administration as an adjunct to diet to
reduce TG levels in adult patients with severe ($500 mg/
dL) hypertriglyceridemia. The MARINE study (Multi-Cen-
ter, PlAcebo-Controlled, Randomized, Double-BlINd, 12-
week study with an open-label Extension)10 was the largest
clinical trial of any u-3 fatty acid agent in this particular
patient population (N 5 229) in which investigators evalu-
ated the efficacy and safety of IPE in patients with very
high TG levels ($500 mg/dL and #2000 mg/dL). In this
study, IPE significantly reduced TG levels (IPE 4 g/day:
233.1%; P , .0001) without increasing LDL cholesterol
levels.10 Among those with baseline TG levels .750 mg/
dL, IPE 4 g/day reduced the placebo-adjusted TG levels
by 45.4% (mean baseline TG level, 902.0 mg/dL;
P 5 .0001).
LDL cholesterol is the primary treatment target for
cholesterol-lowering therapy for prevention of CHD.11 It is
the consensus of many lipidologists that apolipoprotein B
and lipoprotein particle concentration are also important
factors influencing atherogenicity, as well as being poten-
tially useful in the initial assessment and on-treatment lipid
management of hypertriglyceridemic patients at increased
CHD risk.12 This exploratory analysis reports the effects
of IPE on lipoprotein particle concentrations and sizes in
patients with baseline TG levels $500 mg/dL.Methods
MARINE was a phase 3, multicenter, placebo-
controlled, randomized, double-blind, 12-week study that
evaluated the efficacy and safety of IPE in patients with
very high TG levels ($500 mg/dL and #2000 mg/dL).
Details of the MARINE study design and methods were
reported elsewhere.10 In summary, following a 4- to 6-week
lead-in period of diet, lifestyle, medication stabilization,
and washout of prohibited lipid-altering medication, pa-
tients aged .18 years of age entered a 2- to 3-week TG-
qualifying period. Patients with qualifying TG levels
($500 mg/dL and #2000 mg/dL) entered the 12-weekdouble-blind treatment period and were randomized to re-
ceive either IPE 4 g/day, IPE 2 g/day, or matched placebo
(Fig. 1).10 Prohibited lipid-altering therapies that required
a washout period included fibrates, niacins, and u-3 fish
oils. Ezetimibe monotherapy or statins with or without eze-
timibe could be continued throughout the study (unless the
investigator elected to washout these therapies at study en-
try) as long as no change was made in statin type or dose.
Other prohibited concomitant agents included drugs for
weight loss, human immunodeficiency virus protease inhib-
itors, cyclophosphamide, isotretinoin, and systemic cortico-
steroids. The remaining key exclusion criteria were history
of pancreatitis; untreated hypothyroidism; known nephrotic
range (.3 g/day) proteinuria; history of stroke, myocardial
infarction, life-threatening arrhythmia, or coronary vascu-
larization within 6 months before screening; body mass in-
dex .45 kg/m2; weight change .3 kg during the lead-in
period; hemoglobin A1c .9.5%; thyroid-stimulating hor-
mone.1.5! upper limit of normal; thyroid hormone ther-
apy not stable for $6 weeks before screening; alanine
aminotransferase or aspartate aminotransferase .3 ! up-
per limit of normal; unexplained creatine kinase concentra-
tion .3 ! upper limit of normal; or creatine kinase
elevation attributable to known muscle disease.
Lipoprotein measurements
All lipoprotein particle concentration and size assess-
ments were obtained from fasting blood samples which
were collected into tubes containing ethylenediaminetetra-
acetic acid and plasma was isolated via centrifugation
(1200g for 15 minutes) and stored at 220C or lower.
Lipoprotein particle concentration and size were measured
by nuclear magnetic resonance (NMR) spectroscopy13 at
LipoScience, Inc. (Raleigh, NC) using the LipoScience,
Inc. LipoProfile-3 algorithm. Concentrations of the follow-
ing subclasses were analyzed in this study: small LDL
(18.0–20.5 nm), large LDL (20.5–23.0 nm), intermediate-
density lipoprotein (IDL; 23.0–29.0 nm), large high-
density lipoprotein (HDL; 9.4–14.0 nm), medium HDL
(8.2–9.4 nm), small HDL (7.3–8.2 nm), large very-low-
density lipoprotein (VLDL; .60 nm), medium VLDL
(42–60 nm), and small VLDL (29–42 nm). VLDL, LDL,
and HDL subclasses of different size were quantified
from the amplitudes of their spectroscopically distinct lipid
methyl group NMR signals as previously described.13
Statistical methods
This was an exploratory analysis of IPE 4 and 2 g/day
(vs placebo) on lipoprotein particle concentrations and
sizes. Efficacy analyses included the intent-to-treat (ITT)
population, defined as all randomized patients who had a
baseline efficacy measurement, received $1 dose of study
drug, and had$1 postrandomization efficacy measurement.
Because of the lack of a normal distribution of the
lipoprotein particle parameters, medians and interquartile
Figure 1 Study design. Eligible patients entered 4- to 6-week lead-in period (6-week washout period for patients receiving lipid-altering
therapy, 4 weeks for patients not receiving lipid-altering therapy), followed by qualifying TG measurements at visits 2 and 3. If TG levels
were not within the inclusion range, an additional week was allowed for another measurement (adjunct visit 3.1). Qualifying patients were
randomized at Visit 4 and entered the double-blind 12-week safety and efficacy measurement phase.10 IPE, icosapent ethyl.
Bays et al IPE effects on lipoprotein particles 567ranges were calculated for each treatment group at baseline
and week 12. Subjects with missing baseline or week 12
measurements, as the result of either missing laboratory
samples or unreportable values, were excluded from this
analysis. The percent change from baseline was computed
by dividing the week 12 change from baseline by the
baseline value, multiplied by 100. If the baseline value was
zero, then the NMR LipoProfile minimum value for the end
point was used as the divisor. Only three end points
included patients with zero baseline values: particle con-
centration for large LDL (111 patients; minimum value 1.0
nmol/L), small VLDL (2 patients; minimum value 0.1
nmol/L), and large HDL (2 patients; minimum value 0.1
mmol/L), compared with a total of 177 patients in the data
set. The median difference of each lipoprotein particle
variable (percent change from baseline) between each IPE
treatment group and the placebo group was evaluated with
a nonparametric test using the Hodges-Lehmann medians
of the differences between treatment groups and the
Wilcoxon rank-sum test. For exploratory efficacy parame-
ters, including lipoprotein particle size and concentration, it






Age, mean (SD), y 52.1 (9.6) 53.7 (
Age #65 y, n (%) 55 (90) 58 (
Male, n (%) 46 (75) 48 (
White, n (%) 53 (87) 56 (
Weight, mean (SD), kg 92.8 (17.1) 92.8 (
BMI, mean (SD), kg/m2 30.7 (4.1) 30.9 (
Diabetes mellitus, n (%) 18 (29.5) 17 (
High risk for CVD,* n (%) 32 (52.5) 37 (
Apo B, mean (SD), mg/dL 126.1 (28.4) 121.9 (
Apo B, apolipoprotein B; BMI, body mass index; CHD, coronary heart diseas
SD, standard deviation.
Values are reported for patients from the MARINE ITT population for whom
*High CVD risk: patients with clinical CHD or clinical CHD risk equivalents (1
gram Adult Treatment Panel III guidelines.33
†N 5 176.multiplicity, and that significance was defined as a P value
of #.05. All statistical analyses were carried out using SAS
9.2 software.Results
In total, 224 patients were included in the ITT popula-
tion of the MARINE study; 177 of these had evaluable
samples for lipoprotein particle analysis with 61, 63, and 53
patients in the IPE 4 g/day, IPE 2 g/day, and placebo
groups, respectively. The analysis of LDL particle size
contained 60 patients in the IPE 4 g/day group. Baseline
demographics were comparable among treatment groups
(Table 1) and were similar to those reported for the overall
randomized MARINE population.10 The majority of pa-
tients were white, overweight men who were #65 years
of age. The median baseline TG levels were 652, 620,
and 629 mg/dL, and the median baseline LDL cholesterol
levels were 98, 86, and 92 mg/dL for the IPE 4 g/day,
IPE 2 g/day, and placebo groups, respectively (Table 2).
These baseline lipid levels were similar to those reported/day
3) Placebo (n 5 53) Total (N 5 177)
9.2) 53.9 (7.9) 53.2 (9.0)
92) 51 (96) 164 (93)
76) 39 (74) 133 (75)
89) 51 (96) 160 (90)
15.4) 93.5 (17.8) 93.0 (16.6)
4.2) 30.8 (4.4) 30.8 (4.2)
27.0) 16 (30.2) 51 (28.8)
59.7) 30 (56.6) 99 (56.3)†
28.8) 122.3 (32.8) 123.5 (29.8)
e; CVD, cardiovascular disease; IPE, icosapent ethyl; ITT, intent-to-treat;
lipoprotein particle measurements were taken.








































































































































































































































































































































































































































































































































































































































































































































































































568 Journal of Clinical Lipidology, Vol 6, No 6, December 2012for the MARINE ITT population.10 The effects of IPE on
the efficacy end points of TG, LDL cholesterol, and HDL
cholesterol in the patient groups of this analysis (Table 2)
were similar to those of the MARINE ITT population.10
Lipoprotein particle concentrations
Table 3 contains the median placebo-adjusted changes in
lipoprotein particle concentrations. By study end and com-
pared with placebo, IPE 4 g/day significantly reduced the
concentration of large VLDL particles (227.9%; P 5
.0211) and increased the concentration of medium VLDL
particles (128.0%, P 5 .0238) with no significant change
in median concentration of total VLDL particles (19.3%,
P 5 .2262). IPE 2 g/day did not significantly change total,
small, medium, or large VLDL particle concentration. IPE
4 g/day reduced total LDL particle concentration (which in-
cluded IDL particles, small LDL particles, and large LDL
particles) by 16.3% (P 5 .0006). IPE 2 g/day did not signif-
icantly change total LDL particle concentration (21.1%,
P 5 .8202). IPE 4 g/day and 2 g/day both significantly re-
duced small LDL particle concentration by 25.6% (P ,
.0001) and 12.8% (P 5 .0274), respectively, with no signif-
icant changes in concentrations of large LDL or IDL parti-
cles. LDL particle concentration declined numerically more
in statin-treated patients (4 g/day [n 5 16], 230.2%, P 5
.1079; 2 g/day [n 5 15], 222.1%, P 5 .2120) than among
those not receiving statins (4 g/day [n 5 45], 213.2%, P 5
.0054; 2 g/day [n 5 48], 11.7%, P 5 .7176). However, the
number of patients receiving statins was small and statisti-
cal significance was not achieved for the decreases ob-
served in this group.
IPE 4 g/day significantly reduced total HDL particle
concentration (27.4%, P 5 .0063); IPE 2 g/day did not
(23.0%, P 5 .2701). Neither dose of IPE significantly
changed concentrations of large, medium, or small HDL
particles.
The concentration of all LDL and VLDL particles
correlated with apolipoprotein B concentration at Week
12 (R2 5 .623, P , .0001; Fig. 2).
Lipoprotein particle sizes
Table 4 contains the median placebo-adjusted changes in
lipoprotein particle size for IPE. At study end and com-
pared with placebo, IPE 4 g/day significantly decreased
VLDL particle size (28.6%, P 5 .0017). IPE 2 g/day
also decreased VLDL particle size, although not signifi-
cantly (24.0%, P 5 .0734). Neither IPE dose significantly
changed LDL or HDL particle size.Discussion
This exploratory analysis of the MARINE study was the
largest of any u-3 fatty acid study to report lipoprotein




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2 The atherogenic lipoprotein particle concentration cor-
related with apolipoprotein B (ApoB) at week 12 (N 5 177; R2 5
.623; P, .0001). The atherogenic particle concentration consisted
of all VLDL and LDL particles.
Bays et al IPE effects on lipoprotein particles 569and was conducted to examine the effects of IPE, a high-
purity prescription form of EPA ethyl ester, on lipoprotein
particle concentrations and sizes. In this analysis, IPE 4 g/
day significantly reduced the particle concentrations of
large VLDL by 27.9%, total LDL by 16.3%, small LDL by
25.6%, and total HDL by 7.4% compared with placebo in
patients with very high TG levels ($500 and #2000 mg/
dL) and significantly reduced VLDL particle size by 8.6%.
The reduction in total LDL particle concentration with IPE
4 g/day is consistent with the previously reported reduction
in apolipoprotein B levels.10 The reduction in apolipopro-
tein B, as well as the reduction in VLDL particle size, is
consistent with the lipoprotein- and TG-lowering effects
of IPE.3
IPE did not significantly increase LDL cholesterol levels
in the patient population with very high TG levels,10 which
is unique given that other TG-lowering agents such as fi-
brates and fish oil therapies containing both EPA and
DHA increase LDL cholesterol levels, sometimes substan-
tially.3,14 These findings are supported by a recent literature
review that found that DHA treatment was more often asso-
ciated with increases in LDL cholesterol than EPA treat-
ment,15 as well as by a meta-analysis of 21 randomized
clinical trials that concluded that although EPA and DHA
both reduced TG, DHA significantly increased HDL cho-
lesterol and LDL cholesterol, whereas EPA nonsignificantly
reduced LDL cholesterol and caused a nonsignificant in-
crease in HDL cholesterol.16 This lack of LDL cholesterol
increase observed for IPE may correlate with the reduction
in LDL particle concentration observed in this analysis. In
contrast to IPE, a prescription EPA and DHA combination














































































































































































































































































































































































































































































































































































































































































570 Journal of Clinical Lipidology, Vol 6, No 6, December 2012particle concentrations and increases in large LDL particle
concentrations while leaving the concentration of total LDL
particles unchanged.17 Further research is needed to gain a
better understanding of the mechanism of action of IPE rel-
ative to combination EPA and DHA agents.
Organizations such as the American Diabetes Associa-
tion and the American College of Cardiology have
suggested the clinical use of apolipoprotein B and LDL
particle concentration to help assess residual cardiovascular
risk and aid in treatment strategies for patients with
dyslipidemia.18 LDL particle concentration as measured
by NMR,19–21 as well as studies of apolipoprotein B, a sur-
rogate marker of LDL particle concentration,22 are signifi-
cant predictors of cardiovascular risk. The significant
reduction in the concentration of total LDL particles in
this analysis, along with the previously reported reduction
of apolipoprotein B by IPE in the MARINE study,10 may
therefore have clinical significance.
Similar to this current analysis with IPE, in a previous
study of a prescription EPA and DHA combination, inves-
tigators showed a reduction in HDL particle concentration
that was due primarily to reduction in medium but not
small or large HDL particle concentration.17 The clinical
significance of the reduction in HDL particle number is un-
known. However, irrespective of potential effects of omega-
3 fatty acids on HDL particle number, clinical trials support
the cardiovascular benefits of EPA and DHA combination,
as well as EPA alone.23–25 This finding has presumably
contributed to recommendations that HDL subfraction
measurement not be recommended for initial assessment
or on-treatment management of cardiovascular risk.12
Some studies have suggested that smaller LDL particles
are more atherogenic than larger LDL particles26–28 and
that LDL particle size is inversely related to on-treatment
TG levels.17,29 The lack of change in LDL particle size ob-
served in this analysis was expected because changes in
LDL particle size occur most often at TG threshold levels
between 100 and 250 mg/dL,17,29,30 which were levels
largely unachieved due to the very high TG entry criteria
($500 mg/dL). Although baseline lipoprotein particle
size may assist in CHD risk assessment, virtually no data
exist to support that therapeutic changes in lipoprotein par-
ticle size improve CHD outcomes, and the totality of CHD
outcomes evidence suggests that lipid-altering therapy
might best be focused toward reducing LDL cholesterol,
apolipoprotein B, non-HDL cholesterol, and LDL particle
number.31 As with HDL subfraction monitoring, no CHD
outcomes data exist to support LDL subfraction monitoring
for CHD risk assessment or for on-treatment monitoring of
cardiovascular risk.12 Although definitive CHD outcome
data are likewise lacking, assessment of LDL particle num-
ber is sometimes recommended for the initial management
of cardiovascular risk in certain patient populations, such as
those with discordantly elevated LDL particle number12
due to the stronger association of LDL particle number
than LDL cholesterol with risk of CVD events in these
patients.19
Bays et al IPE effects on lipoprotein particles 571Although neither the MARINE study nor the present
analysis assessed CHD outcomes, in previous study, authors
supported that a strategy of EPA therapy has the potential to
reduce CHD events.32 Regarding IPE, the evidence to date
suggests that this agent significantly lowers TG and apolip-
oprotein B levels without increasing LDL cholesterol.10
The ongoing Reduction of Cardiovascular Events With
EPA-Intervention (REDUCE-IT; NCT1492361) study will
evaluate the effect of IPE on prevention of a first major car-
diovascular event in approximately 8000 patients with hy-
pertriglyceridemia at high risk for cardiovascular events,
and will provide important information about the utility
of IPE for therapy in patients at risk for cardiovascular
disease.
Conclusions
In this 12-week study of patients with TG levels $500
and #2000 mg/dL, IPE 4 g/day significantly reduced large
VLDL, total LDL, small LDL, and total HDL particle
concentrations and VLDL particle size. The reduction in
LDL particle concentration observed with IPE therapy is
novel among u-3 therapies and is consistent with the
previously reported reduction in apolipoprotein B concen-
tration and lack of LDL cholesterol concentration increase
in patients with very high TG levels treated with IPE.
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